Lymphoma Clinical Trials in Atlanta

Showing 421-440 of 632 trials

Safety and Efficacy Study of a Dual PI3K Delta/Gamma Inhibitor in T-cell Lymphoma

NCT02567656

The purpose of this study is to evaluate the safety, PK and efficacy of RP6530, a dual PI3K delta/gamma inhibitor in patients with relapsed and refractory T-cell Lymphoma.

Lymphoma, T-Cell, PeripheralLymphoma, T-Cell, Cutaneous

Rhizen Pharmaceuticals SA58 participantsStarted Sep 2015

Duarte, California, United States • Orange, California, United States • Aurora, Colorado, United States +5 more locations

COMPLETED< 1 mile

Comprehensive Oncology Measures for Peripheral T-cell Lymphoma Treatment Registry

NCT01110733

Prospective, longitudinal, multinational, observational study that will collect data on how patients with peripheral T-cell lymphoma (PTCL) are treated in academic and community practices.

Peripheral T-cell Lymphoma

Acrotech Biopharma Inc.3,000 participantsStarted Feb 2010

Tuscaloosa, Alabama, United States • Tucson, Arizona, United States • Hot Springs, Arkansas, United States +65 more locations

Safety and Efficacy Study of a Dual PI3K Delta/Gamma Inhibitor in T-cell Lymphoma

Comprehensive Oncology Measures for Peripheral T-cell Lymphoma Treatment Registry

Lymphoma Trials in Other Cities

The Second Multicenter Hemophilia Cohort Study

Study of Lenalidomide to Evaluate Safety and Effectiveness in Patients With Diffuse Large B-Cell Lymphoma (DLBCL)

Study Evaluating Two Dose Levels of Targretin Capsules in Participants With Refractory Cutaneous T-Cell Lymphoma (CTCL)

A Phase 3 Study of Ibrutinib (PCI-32765) Versus Ofatumumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia

Phase 1 Dose Finding Study of Belinostat for Treatment of Patients With Peripheral T-cell Lymphoma (PTCL)

Monoclonal Antibody Therapy and Combination Chemotherapy in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma

Safety and Efficacy Study of RP4010, in Patients With Relapsed or Refractory Lymphomas

Influence of Rifampin on the Pharmacokinetics of Romidepsin in Patients With Advanced Cancer

A Single Agent Phase II Study of Romidepsin (Depsipeptide, FK228) in the Treatment of Cutaneous T-cell Lymphoma (CTCL)

Alemtuzumab Plus Fludarabine and Melphalan With or Without Cyclosporine, Mycophenolate Mofetil, and Low-Dose Total-Body Irradiation Therapy Followed by Donor Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer

Rituximab, Pentostatin, Cyclophosphamide, and Lenalidomide in Treating Patients With Previously Untreated B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Everolimus in Treating Patients With Lymphoma That Has Relapsed or Not Responded to Previous Treatment

A Safety and Pharmacology Study of Atezolizumab (MPDL3280A) Administered With Obinutuzumab or Tazemetostat in Participants With Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma

Safety & Pharmacokinetics Study Of Azacitidine (SC And Oral) In Subjects With MDS, CMML, AML, Lymphoma And Multiple Myeloma

A Phase 2 Multi-Center Study of Entinostat (SNDX-275) in Patient With Relapsed or Refractory Hodgkin's Lymphoma

Fludarabine Phosphate and Total-Body Radiation Followed by Donor Peripheral Blood Stem Cell Transplant and Immunosuppression in Treating Patients With Hematologic Malignancies

Study to Evaluate the Efficacy and Safety of AMG 714 in Adult Patients With Type II Refractory Celiac Disease

An Extension Study of ABT-199 in Subjects With Advanced Non-Hodgkin's Lymphoma

Other Conditions in Atlanta